150
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report

, , &
Pages 765-769 | Received 30 Mar 2023, Accepted 10 Jul 2023, Published online: 26 Jul 2023

Figures & data

Figure 1 Summary of disease course, therapies, and molecular findings. (A) The entire treatment course; (B) Chest CT scans of the primary PSC at treatment milestones; red arrows indicate nodular thickening of the pleura. (C) Pleuroscopy revealed multiple neoplasms in the right parietal pleura, visceral pleura, and phrenic pleura.

Abbreviations: CT, computed tomography; NGS, next-generation sequencing; PR, partial response; PSC, pulmonary sarcomatoid carcinoma.
Figure 1 Summary of disease course, therapies, and molecular findings. (A) The entire treatment course; (B) Chest CT scans of the primary PSC at treatment milestones; red arrows indicate nodular thickening of the pleura. (C) Pleuroscopy revealed multiple neoplasms in the right parietal pleura, visceral pleura, and phrenic pleura.

Figure 2 Hematoxylin-eosin (HE) and immunohistochemistry staining on the biopsy sample of the right parietal pleura. The rulers in indicate 50 μm.

Figure 2 Hematoxylin-eosin (HE) and immunohistochemistry staining on the biopsy sample of the right parietal pleura. The rulers in Figure 2 indicate 50 μm.

Figure 3 The integrative genomics viewer (IGV) screenshots revealed the harboring of KIF5B-RET fusion.

Figure 3 The integrative genomics viewer (IGV) screenshots revealed the harboring of KIF5B-RET fusion.